Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.
Mavorixafor is a prescription CXC chemokine receptor 4 antagonist marketed as Xolremdi. It is indicated for patients age 12 and older with WHIM syndrome, a rare immune disorder involving warts, hypogammaglobulinemia, infections, and myelokathexis. Treatment increases circulating mature neutrophils and lymphocytes. Each capsule contains 100 mg of mavorixafor.
read more about mavorixafor ...Mavorixafor blocks the CXCR4 receptor and interferes with its interaction with CXCL12. This reduces the retention of certain white blood cells in the bone marrow, increasing the number of mature neutrophils and lymphocytes circulating in the bloodstream.
Mavorixafor is used in adults and adolescents age 12 and older with WHIM syndrome. Treatment is intended to increase circulating neutrophils and lymphocytes rather than directly treat an active infection. Patients undergo assessment of heart rhythm risks, pregnancy status when applicable, and potential drug interactions before treatment.
Patients weighing more than 50 kg receive 400 mg by mouth once daily, while patients weighing 50 kg or less receive 300 mg once daily. Capsules are taken on an empty stomach after an overnight fast and at least 30 minutes before food. They are swallowed whole. Strong CYP3A4 inhibitors require a reduced daily dose of 200 mg.
Mavorixafor can prolong the QT interval and increase the risk of abnormal heart rhythms. It can also cause fetal harm, so pregnancy testing and contraception are part of treatment precautions. Other adverse reactions include thrombocytopenia, rash, rhinitis, nosebleeds, vomiting, and dizziness. Use with medicines highly dependent on CYP2D6 for clearance is contraindicated.
Mavorixafor is indicated for WHIM syndrome in patients age 12 and older to increase circulating mature neutrophils and lymphocytes.
The recommended dose is 400 mg once daily.
Capsules are swallowed whole on an empty stomach after an overnight fast, at least 30 minutes before eating.
Yes. Mavorixafor can prolong the QT interval, particularly when combined with certain interacting medicines.
DailyMed - XOLREMDI (mavorixafor) capsule. https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7f3a5ee3-ca73-4876-85a0-ed1e108a2237. Date Accessed October 14, 2026.
Drug Trials Snapshots - XOLREMDI. U.S. Food and Drug Administration. https://www.fda.gov/drugs/drug-trials-snapshots/drug-trials-snapshots-xolremdi. Date Accessed October 14, 2026.
FDA Approves First Drug for WHIM Syndrome, a Rare Disorder That Can Lead to Recurrent, Life-Threatening Infections. U.S. Food and Drug Administration. https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-first-drug-whim-syndrome-rare-disorder-can-lead-recurrent-life-threatening-infections. Date Accessed October 14, 2026.
Mavorixafor. MedlinePlus. https://medlineplus.gov/druginfo/meds/a624036.html. Date Accessed October 14, 2026.
Mavorixafor. PubChem. https://pubchem.ncbi.nlm.nih.gov/compound/Mavorixafor. Date Accessed October 14, 2026.